undamentalytics Newsletter
Sign in

Aurinia Pharmaceuticals Inc. revenue

Aurinia Pharmaceuticals Inc.'s revenue was $283m in fiscal 2025, up 20.4% on the year before. Since fiscal 2016 ($173,000) it has grown at a compound 127.6% a year. Over the last twelve months it was $322m.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2016Dec 20162017Dec 20172018Dec 20182019Dec 20192020Dec 20202021Dec 20212022Dec 20222023Dec 20232024Dec 20242025Dec 2025LTMSept 2026
Revenue00005046134176235283322
Growth on the year before—+141.6%+10.8%−31.3%+>999%−9.0%+193.9%+31.0%+34.0%+20.4%—
Gross profit———05045128161207250292
Gross margin———100.0%100.0%97.6%95.8%91.9%88.0%88.5%90.6%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Where the revenue comes from

Fiscal year to December 31, 2025
Products and services
Line of business Revenue Share YoY
Products $271M 95.9% ▲ 25.5%
License Collaboration and Royalty Revenue $11.7M 4.1% ▼ 38.2%
Geography
Region Revenue Share YoY
United States $264M 93.2% ▲ 25.6%
Japan $19.2M 6.8% ▼ 23.3%

From Aurinia Pharmaceuticals Inc.'s 10-K filed February 26, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Aurinia Pharmaceuticals Inc. $322m 21.0% 26.5%
Iovance Biotherapeutics, Inc. $325m 34.5% —
Arvinas, Inc. $317m -15.0% 26.1%
Adaptive Biotechnologies Corp $308m 50.1% 17.6%
Vericel Corp $306m 23.0% 19.8%
Vir Biotechnology, Inc. $303m 1495.9% -14.8%

Compare with peers

Head to head: AUPH vs IOVAARVN vs AUPHADPT vs AUPH

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Aurinia Pharmaceuticals Inc.'s SEC filings (10-K and 10-Q), retrieved November 3, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Aurinia Pharmaceuticals Inc.